These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 21079617

  • 1. No compelling evidence that sibutramine prolongs life in rodents despite providing a dose-dependent reduction in body weight.
    Smith DL, Robertson HT, Desmond RA, Nagy TR, Allison DB.
    Int J Obes (Lond); 2011 May; 35(5):652-7. PubMed ID: 21079617
    [Abstract] [Full Text] [Related]

  • 2. Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat.
    Wellman PJ, Jones SL, Miller DK.
    Pharmacol Biochem Behav; 2003 Apr; 75(1):103-14. PubMed ID: 12759118
    [Abstract] [Full Text] [Related]

  • 3. 5-HT(1A) activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats.
    Thomas GH, Babbs AJ, Chatfield RE, Krülle TM, Widdowson PS, Provost D, McCormack JG.
    Obesity (Silver Spring); 2009 Mar; 17(3):467-73. PubMed ID: 19219064
    [Abstract] [Full Text] [Related]

  • 4. Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats.
    Tallett AJ, Blundell JE, Rodgers RJ.
    Behav Brain Res; 2009 Mar 17; 198(2):359-65. PubMed ID: 19061919
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
    Smith IG, Goulder MA, Sibutramine Clinical Study 1047 Team.
    J Fam Pract; 2001 Jun 17; 50(6):505-12. PubMed ID: 11407998
    [Abstract] [Full Text] [Related]

  • 7. Regulation of body weight and carcass composition by sibutramine in rats.
    Strack AM, Shu J, Camacho R, Gorski JN, Murphy B, MacIntyre DE, Hickey GJ.
    Obes Res; 2002 Mar 17; 10(3):173-81. PubMed ID: 11886940
    [Abstract] [Full Text] [Related]

  • 8. Locomotor and peripheral effects of sibutramine modulated by 5-HT2 receptors.
    Frassetto SS, Della Santa Rubio A, Lopes JJ, Pereira P, Brum C, Khazzaka M, Vinagre AS.
    Can J Physiol Pharmacol; 2006 Dec 17; 84(12):1239-44. PubMed ID: 17487231
    [Abstract] [Full Text] [Related]

  • 9. [Sibutramine--antidepressive agent tested against obesity].
    Rössner S.
    Lakartidningen; 2001 Apr 11; 98(15):1802-3. PubMed ID: 11374008
    [Abstract] [Full Text] [Related]

  • 10. Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats.
    Grignaschi G, Fanelli E, Scagnol I, Samanin R.
    Br J Pharmacol; 1999 Jul 11; 127(5):1190-4. PubMed ID: 10455265
    [Abstract] [Full Text] [Related]

  • 11. Sibutramine. A review of its contribution to the management of obesity.
    McNeely W, Goa KL.
    Drugs; 1998 Dec 11; 56(6):1093-124. PubMed ID: 9878996
    [Abstract] [Full Text] [Related]

  • 12. Comparative study of fluoxetine, sibutramine, sertraline and dexfenfluramine on the morphology of serotonergic nerve terminals using serotonin immunohistochemistry.
    Kalia M, O'Callaghan JP, Miller DB, Kramer M.
    Brain Res; 2000 Mar 06; 858(1):92-105. PubMed ID: 10700602
    [Abstract] [Full Text] [Related]

  • 13. Effects of sibutramine on resting metabolic rate and weight loss in overweight women.
    Seagle HM, Bessesen DH, Hill JO.
    Obes Res; 1998 Mar 06; 6(2):115-21. PubMed ID: 9545017
    [Abstract] [Full Text] [Related]

  • 14. Locomotion is the major determinant of sibutramine-induced increase in energy expenditure.
    Golozoubova V, Strauss F, Malmlöf K.
    Pharmacol Biochem Behav; 2006 Apr 06; 83(4):517-27. PubMed ID: 16647108
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
    Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P.
    Int J Obes Relat Metab Disord; 1998 Jan 06; 22(1):32-8. PubMed ID: 9481597
    [Abstract] [Full Text] [Related]

  • 16. Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.
    Mashiko S, Ishihara A, Iwaasa H, Moriya R, Kitazawa H, Mitobe Y, Ito J, Gomori A, Matsushita H, Takahashi T, MacNeil DJ, Van der Ploeg LH, Fukami T, Kanatani A.
    Obesity (Silver Spring); 2008 Jul 06; 16(7):1510-5. PubMed ID: 18421274
    [Abstract] [Full Text] [Related]

  • 17. Sibutramine: a review of the pharmacology of a novel anti-obesity agent.
    Stock MJ.
    Int J Obes Relat Metab Disord; 1997 Mar 06; 21 Suppl 1():S25-9. PubMed ID: 9130038
    [Abstract] [Full Text] [Related]

  • 18. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat.
    Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ.
    Br J Pharmacol; 1997 Aug 06; 121(8):1613-8. PubMed ID: 9283694
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats.
    Rowley HL, Butler SA, Prow MR, Dykes SG, Aspley S, Kilpatrick IC, Heal DJ.
    Synapse; 2000 Nov 06; 38(2):167-76. PubMed ID: 11018791
    [Abstract] [Full Text] [Related]

  • 20. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
    Van Gaal LF, Wauters MA, De Leeuw IH.
    Exp Clin Endocrinol Diabetes; 1998 Nov 06; 106 Suppl 2():35-40. PubMed ID: 9792480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.